

DESCRIPTION

Source	Chinese Hamster Ovary cell line, CHO-derived				
	Mouse Integrin α E (Phe20-Arg1113, Ser453Gly) Accession # ABD49099	His-Pro	GGSGGGGS	Acidic Tail	6-His tag
	Mouse Integrin β 7 (Glu20-Arg724) Accession # P26011	GGSGGGGS	Basic Tail		
	N-terminus			C-terminus	

N-terminal Sequence Phe20 & Thr183 (α E), Glu20 (β 7)

Analysis

Structure / Form Non-covalent heterodimer

Predicted Molecular Mass 130 kDa (α E), 84 kDa (β 7)

SPECIFICATIONS

SDS-PAGE	112-128 kDa and 142-176 kDa, reducing conditions
Activity	Measured by its binding ability in a functional ELISA. When Recombinant Mouse E-Cadherin Fc Chimera (Catalog # 748-EC) is coated at 2 μ g/mL, Recombinant Mouse Integrin α E β 7 binds with an apparent K_d <2.5 nM.
Endotoxin Level	<0.10 EU per 1 μ g of the protein by the LAL method.
Purity	>95%, by SDS-PAGE with silver staining.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 μ g/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Integrin α E β 7 (also called M290 in mouse and HML-1 in human) is a type I transmembrane adhesion protein. It is composed of an α E subunit (epithelial-associated; also designated as CD103) which is expressed as disulfide-linked 150 kDa and 25 kDa heavy and light chains, and a non-covalently associated 130 kDa β 7 glycoprotein subunit (1, 2). Each subunit has a transmembrane sequence and a short cytoplasmic tail. Integrin α E β 7 is the only known integrin family receptor containing the α E subunit, while the β 7 subunit is also a component of Integrin α 4 β 7 (1-3). The α E extracellular domain (ECD) contains 7 β -propeller domains surrounding an I domain followed by domains called tight, calf-1 and calf-2. An extra X domain, not found in any other alpha integrin, is also present and contains a proteolytic cleavage site (1, 2). The β 7 ECD contains a vWFA domain, which interacts with the α E β -propeller to form a binding domain. The MIDAS motif (metal ion dependent adhesion site) is critical for binding of α E β 7 to its ligand, E-Cadherin (4). The 1093 amino acid (aa) mouse α E extracellular domain shares 79% and 99% aa sequence identity with human and rat α E respectively, while the 704 aa mouse β 7 ECD shares 87% and 94% aa identity with human and rat β 7, respectively. Integrin α E β 7 is mainly restricted to mucosal tissues, where it engages E-Cadherin (4-6). It was first identified as a marker of intestinal intra-epithelial lymphocytes (1, 5, 6). It has since been recognized that a variety of leukocytes, such as cytotoxic CD8⁺ T cells, some dendritic cells, and effector/memory-like regulatory T cells, acquire Integrin α E β 7 in the days following their migration to epithelium in the intestines, lungs, and tonsils (6-13). In these tissues Integrin α E β 7 facilitates immune surveillance, including the destruction of infected or transformed epithelial cells and the induction of T cell adaptive responses (7-13). Pathologically, Integrin α E β 7 may be involved in allograft rejection of transplanted pancreatic islets and other tissues (14).

References:

- Shaw, S.K. *et al.* (1994) J. Biol. Chem. **269**:6016.
- Erle, D.J. *et al.* (1991) J. Biol. Chem. **266**:11009.
- Luo, B-H. *et al.* (2007) Annu. Rev. Immunol. **25**:619.
- Higgins, J.M.G. *et al.* (2000) J. Biol. Chem. **275**:25652.
- Cepek, K.L. *et al.* (1994) Nature **372**:190.
- Wagner, N. *et al.* (1996) Nature **382**:366.
- Le Floch, A. *et al.* (2007) J. Exp. Med. **204**:559.
- Smyth, L.J.C. *et al.* (2007) Clin. Exp. Immunol. **149**:162.
- Woodberry, T. *et al.* (2005) J. Immunol. **175**:4355.
- Jaensson, E. *et al.* (2008) J. Exp. Med. **205**:2139.
- del Rio, M.-L. *et al.* (2008) J. Immunol. **181**:6178.
- Sung, S.J. *et al.* (2006) J. Immunol. **176**:2161.
- Siewert, C. *et al.* (2008) J. Immunol. **180**:146.
- Feng, Y. *et al.* (2002) J. Exp. Med. **196**:877.